



DOCKET NO.: **ISIS0040-100 (RTS-0303)**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Bennett and Dobie**

Serial No.: **10/020,478**

Group Art Unit: **1635**

Filed: **December 13, 2001**

Examiner: **Jane J Zara**

Title: **Antisense Modulation Of B-Cell Associated Protein Expression**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

DECLARATION UNDER 37 CFR §1.132

I, Dr. Susan Freier, a citizen of the United States, residing at 2946 Renault Street, San Diego, CA 92122, state and declare as follows:

1. I hold a B.A. in Mathematics (1972) from Carleton College, Northfield, Minnesota and a Ph.D. in Chemistry (1976) from the University of California, Berkeley, California.
2. I have been employed by Isis Pharmaceuticals, Inc. ("Isis"), for about fourteen years. Isis, the assignee of the above-identified patent application, specializes in oligonucleotide technology and uses the latest in bioinformatics programs to identify sites on selected genes for oligonucleotide screening. I am presently the Executive Director of antisense lead identification at Isis and am responsible for several projects. I lead a project utilizing antisense oligonucleotides for functional genomics of novel targets, including the use of computational genomics to characterize target RNAs and their variants, rapid throughput screening to identify active antisense oligonucleotides for novel targets, and Q-RT-PCR and microarrays for expression analysis. I also lead a project for determining microRNA function in mammals, including the use of computational identification of microRNAs and microRNA targets and the use of functional genomics to characterize microRNA biology and identify therapeutic applications of modulation

of miRNA activity. In addition, I lead a group charged with the identification and characterization of novel mechanisms for antisense oligonucleotides, including the use of computational genomics to identify mRNA variants, alteration of RNA processing, evaluation of siRNA and miRNA mechanisms. Another project I am responsible for involves biophysical and biochemical evaluation of novel antisense oligonucleotides, including the evaluation of thermodynamics and kinetics of hybridization to oligonucleotide and large structured targets, evaluation of the biochemical properties of novel oligonucleotides, characterization of antisense activity in cell assays, and protein-oligonucleotide binding.

3. As early as 1995, I performed and supervised experimentation employing oligomeric compounds and inhibition of mRNA expression. My work has involved designing assays to screen oligomeric compounds against specific genes as well as interpreting the results from such assays. I have authored or co-authored numerous scientific journal articles regarding the same. I am an expert in the art of antisense technology and oligonucleotide screening. A copy of my *curriculum vitae* is attached as Exhibit 1.

4. I have read the Office Action dated May 5, 2004 and understand that claims 1, 2, 4-16, and 21-26 of the above-identified application have been rejected as allegedly being obvious over the combination of the following references: Montano *et al.* Milner *et al.* (Nature Biotechnology, 15:537-541, hereinafter, the "Milner reference") and McKay (U.S. Patent No. 6,133,246 ,hereinafter, the "McKay reference"). I make this declaration to rebut the statements in the Office Action regarding the alleged reasonable expectation of success by one of skill in the art for inhibiting the expression of B-Cell Associated Protein.

5. It is not currently possible to predict the level of inhibition of expression achieved against a particular gene with any particular oligomeric compound prior to carrying out the appropriate experiments. It is also not reasonable to expect for any particular gene or mRNA that any number of oligomeric compounds exhibiting at least 42% inhibition of expression, as stated in claim 1 of the present application, will be obtained.

6. Each gene is unique. For instance, if one skilled in the art achieved at least 42% inhibition in the expression of a first gene with oligonucleotides that are targeted to the first gene, one skilled in the art **would not** reasonably expect success in achieving at least 42% inhibition in the expression of a **different** gene with a **different** set of oligomeric compounds that are targeted to the different gene or mRNA. The level of inhibition of expression that is observed for one target has no bearing on the level of inhibition of expression expected for a different target.

7. For example, as indicated by Exhibits 2 (inhibition of human tyrosine kinase, non-receptor, 1 mRNA expression in T-24 cells) and 3 (inhibition of rat urate anion exchanger 1 mRNA expression in Rin-M cells), 80 oligomeric compounds (each being 2'-O-methoxyethyl gapmers) were examined for their ability to inhibit expression (please note that the results are presented as % expression of the control). Referring to Exhibits 2 and 3, no oligomeric compounds were able to inhibit expression by at least 42%. It is **currently not** possible to predict **before** the appropriate experiment is performed, which targets will generate oligomeric compounds that will have a desired level of inhibition of expression.

8. This evidence demonstrates that one skilled in screening of oligomeric compounds cannot, *a priori*, reasonably expect a particular level of inhibition (i.e., such as at least 42%) of a gene or mRNA simply because methods of screening oligomeric compounds are available and/or routine. It is not acceptable to extrapolate results obtained for oligomeric compounds targeted to a particular gene to the results that would be reasonably expected for a different set of oligomeric compounds targeted to a different gene. Thus, the statements in the Office Action regarding reasonable expectation of success are neither accurate nor capable of being supported.

9. I am well aware that numerous U.S. Patents have been issued for oligomeric compounds that are able to inhibit the expression of a particular gene or mRNA. As stated above, however, the level of inhibition of expression that is observed for one particular target has no bearing on the level of inhibition of expression that can reasonably be expected for a different target. Indeed,

targets for which no inhibition or unsatisfactorily low inhibition of expression is achieved are rarely, if ever, the subject of a publication in a scientific journal, let alone are the subject of a patent application.

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: _____

By: _____

Susan Freier, Ph.D.

Attachments:

Exhibits 1, 2 and 3



CURRICULUM VITAE

Susan M. Freier
2946 Renault Street
San Diego, California 92122
(858) 453-7973

Executive Director Antisense Lead Identification
ISIS Pharmaceuticals
2292 Faraday Avenue
Carlsbad, California 92008
(760) 603-2345
(760) 603-4656 (FAX)
sfreier@isisph.com

EDUCATION:

University of California, Berkeley, California
Ph.D in Chemistry, 1976

Carleton College, Northfield, Minnesota
B.A. in Mathematics, summa cum laude, 1972

AWARDS:

Damon Runyon-Walter Winchell Cancer Fund
Fellow (1976-1978)
California Regents Fellow (1974-1976)
NSF Graduate Trainee (1972-1973)

OTHER:

Served on Genome Study Section NIH 1997-2002,
Chair 2000-2002

EXPERIENCE:

ISIS
Pharmaceuticals
San Diego
1990-present

Current title: *Executive Director Antisense Lead Identification*

- Determination of microRNA function in mammals. Includes computational identification of miRNAs and miRNA targets. Functional genomics to characterize miRNA biology and identify therapeutic applications of modulation of miRNA activity.
- Use of antisense oligonucleotides for functional genomics of novel targets. Includes: Computational genomics to characterize target RNAs and their variants, rapid throughput screening to identify active antisense oligonucleotides for novel targets, Q-RT-PCR and microarrays for expression analysis.
- Identification and characterization of novel mechanisms for antisense oligonucleotides. Includes computational genomics to identify mRNA variants, alteration of RNA processing, evaluation of siRNA and miRNA mechanisms.
- Biophysical and biochemical evaluation of novel antisense oligonucleotides. Includes: thermodynamics and kinetics of hybridization to oligonucleotide and large structured targets, evaluation of biochemical properties novel

oligonucleotides, characterization of antisense activity in cell assays, protein-oligonucleotide binding.

- Characterization and screening of combinatorial libraries. Includes: theoretical and experimental evaluation of strategies for deconvolution, high throughput screening of combinatorial libraries, bacterial RNA-protein interactions.

Molecular
Biosystems Inc.
San Diego
1986-1990

- Development of non-radioactive DNA oligonucleotide probe based tests for detection of infectious and genetic diseases. Experience in: isolation of DNA from clinical samples, probe design, hybridization optimization, assay simplification, process validation. Includes: development of FDA cleared clinical tests for the direct detection of rotavirus or *Campylobacter* in stool, development of colony filter tests for bacterial identification and *in situ* hybridization tests for detection of virus in fixed tissues, cultured cells or patient specimens.

University of
Rochester
Rochester NY
1979-1985

- Postdoctoral research with Douglas H. Turner on nucleic acid structure and dynamics. Experience in: chemical and enzymatic synthesis of oligonucleotides (deoxy- and ribo-), hybridization thermodynamics and kinetics, development of a laser temperature jump apparatus, NMR spectroscopy, computer programming and interfacing to laboratory instruments.

Northwestern
University
Evanston IL
1976-1979

- Postdoctoral research with Irving M. Klotz and Richard P. Van Duyne on resonance Raman spectroscopy of DNA-mutagen interactions and resonance Raman spectroscopy of hemerythrin. Experience in: protein isolation, laser Raman spectroscopy.

University of
California
Berkeley, CA
1972-1976

- Graduate research on the solution conformation of transfer RNA.
Thesis title: Studies of Nucleic Acid Chemistry:
Part I. The Solution Structure of Yeast Initiator Transfer RNA Studied by Oligonucleotide Binding
Part II. A Chemical Model of Mutagenesis
Experience in: isolation of tRNA, oligoribonucleotide synthesis, oligonucleotide hybridization, NMR spectroscopy.
Research Advisor: Ignacio Tinoco Jr.

PUBLICATIONS

Barry M. Casper and Susan M. Freier, "'Gibbs Paradox' Paradox", *American Journal of Physics* **41**, 509-511 (1973).

Barry M. Casper, Susan M. Freier and David Van Atta, "Time Evolution in Statistical Mechanics", *American Journal of Physics* **41**, 1358-1360 (1973).

Susan M. Freier and Ignacio Tinoco, Jr. "The Binding of Complementary Oligoribonucleotides to Yeast Initiator Transfer RNA", *Biochemistry* **14**, 3310-3314 (1975).

Joseph A. Walder, Roxanne Y. Walder, Michael J. Heller, Susan M. Freier, Robert L. Letsinger and Irving M. Klotz, "Complementary Carrier Peptide Synthesis: General Strategy and Implications for Prebiotic Origin of Peptide Synthesis", *Proc. Nat. Acad. Sci. U.S.A.* **76**, 51-55 (1979).

Susan M. Freier, Lori L. Duff, Richard P. Van Duyne and Irving M Klotz, "Resonance Raman Studies of a Sulfide Complex of Methemerythrin", *Biochemistry* **24**, 5372-5377 (1979).

Susan M. Freier, Lori L. Duff, Duward F Shriver and Irving M Klotz, "Resonance Raman Spectroscopy of Iron-Oxygen Vibrations in Hemerythrin", *Arch. Biochem. Biophys.* **205**, 449-463 (1980).

Susan M. Freier, K. O. Hill, T. G. Dewey, Luis, A. Markey, Kenneth J. Breslauer and Douglas H. Turner, "Solvent Effects on the Kinetics and Thermodynamics of Stacking in Poly(cytidylic acid)", *Biochemistry* **20**, 1419-1426 (1981).

Douglas H. Turner, Matthew Petersheim, Diane DePrisco Albergo, T. G. Dewey and Susan M. Freier, "Why Do Nucleic Acids Form Helices?", in *Biomolecular Stereodynamics*, R. H. Sarma, ed. Adenine Press, Albany, NY., Vol I, 429-438 (1981).

Susan M. Freier, Diane DePrisco Albergo and Douglas H. Turner, "Solvent Effects on the Dynamics of (dG-dC)₃", *Biopolymers* **22**, 1107-1131 (1983).

Susan M. Freier, Barbara J. Burger, Dirk Alkema, Thomas Neilson and Douglas H. Turner, "Effects of 3' Dangling End Stacking on the Stability of GGCC and CCGG Double Helices", *Biochemistry* **22**, 6198-6206 (1983).

Susan M. Freier, Matthew Petersheim, David R. Hickey and Douglas H. Turner, "Thermodynamic Studies of RNA Stability", *J. Biomol. Struct. Dyn.* **1**, 1229-1242 (1984).

Susan M. Freier, Dirk Alkema, Alison Sinclair, Thomas Neilson and Douglas H. Turner, "Contributions of Dangling End Stacking and Terminal Base-Pair Formation to the Stabilities of XGGCCp, XCCGGp, XGGCCYp, and XCCGGYp Helices", *Biochemistry* **24**, 4533-4539 (1985).

Susan M. Freier, Alison Sinclair, Thomas Neilson and Douglas H. Turner, "Improved Free Energies for G:C Base Pairs", *J. Mol. Biol.* **185**, 645-647 (1985).

Douglas H. Turner, Susan M. Freier, Naoki Sugimoto, David R. Hickey, John J. Jaeger, Alison Sinclair, Dirk Alkema, Thomas Neilson, M. H. Caruthers and Ryszard Kierzek, "Improved Parameters for Predictions of RNA Secondary Structures and Insights Into Why RNA Forms Double Helices", in *Structure and Dynamics of RNA*, (P. H. van Knippenberg and C. W. Hilbers, Eds.) Plenum, New York, 1-13 (1986).

Susan M. Freier, Ryszard Kierzek, Marvin H. Caruthers, Thomas Nielson and Douglas H. Turner, "Free Energy Contributions of G•U and other Terminal Mismatches to Helix Stability", *Biochemistry* **25**, 3209-3213 (1986).

Susan M. Freier, Naoki Sugimoto, Alison Sinclair, Dirk Alkema, Thomas Neilson, Ryszard Kierzek, Marvin H. Caruthers and Douglas H. Turner, Stability of XGCGCp, GCGCYp, and XGCGCYp Helices: An Empirical Estimate of the Energetics of Hydrogen Bonds in Nucleic Acids", *Biochemistry* **25**, 3214-3219 (1986).

Naoki Sugimoto, Ryszard Kierzek, Susan M. Freier and Douglas H. Turner, "Energetics of Internal GU Mismatches in Ribooligonucleotide Helices", *Biochemistry* **25**, 5755-5759 (1986).

Ryszard Kierzek, Marvin H. Caruthers, Carl E. Longfellow, David Swinton, Douglas H. Turner and Susan M. Freier, "Polymer-Supported RNA Synthesis and Its Application To Test the Nearest-Neighbor Model for Duplex Stability", *Biochemistry* **25**, 7840-7846 (1986).

Susan M. Freier, Ryszard Kierzek, John J. Jaeger, Naoki Sugimoto, Marvin H. Caruthers, Thomas Neilson and Douglas H. Turner, "Improved free-energy parameters for predictions of RNA duplex stability", *Proc. Natl. Acad. Sci. USA* **83**, 9373-9377, (1986).

Douglas H. Turner, Naoki Sugimoto and Susan M. Freier, "Thermodynamics and Kinetics of Base-Pairing and of DNA and RNA Self-Assembly and Helix Coil Transition", in *Landolt-Bornstein Numerical Data and Funcational Relationships in Science and Technology*, W. Saenger, ed., Springer-Verlag, Berlin. Group VII: Biophysics, Volume 1: Nucleic Acids, Subvolume c: Spectroscopic and Kinetic Data, Physical Data I, 201-227 (1990)

Douglas H. Turner, Naoki Sugimoto and Susan M. Freier, "RNA Structure Prediction", *Ann. Rev. Biophys. Biophys. Chem.* **17**, 167-192, (1988).

D. H. Turner, N. Sugimoto, J. A. Jaeger, C. E. Longfellow, S. M. Freier and R. Kierzek, "Improved Parameters for Prediction of RNA Structure", *Cold Spring Harbor Symp. Quant. Biol.* **LII**, 123-133 (1988).

Douglas H. Turner, Naoki Sugimoto, Scott D. Dreiker, Susan M. Freier and Ryszard Kierzek, "Hydrogen Bonding and Stacking Contributions to Nucleic Acid Stability", in *Structure and Expression, Volume I: From Proteins to Ribosomes*, R. H. Sarma and M. H. Sarma, eds. Adenine press, Albany, NY. Vol I, 249-259 (1988).

Alison P. Williams, Carl E. Longfellow, Susan M. Freier, Ryszard Kierzek and Douglas Turner, "Laser Temperature-Jump, Spectroscopic, and Thermodynamic Study of Salt Effects on Duplex Formation by dGCATGC", *Biochemistry* **28**, 4283-4291 (1989).

Y. S. Sanghvi, G. D. Hoke, M. C. Zounes, S. M. Freier, J. F. Martin, H. Chan, O. L. Acevedo, D. J. Ecker, C. K. Mirabelli, S.T. Crooke and P. D. Cook, "Synthesis and Biological Evaluation of Antisense Oligonucleotides Containing Modified Pyrimidines", *Nucleosides & Nucleotides* **10**, 345-346 (1991).

Glenn D. Hoke, Kenneth Draper, Susan M. Freier, C. Gonzalez, Vickie B. Driver, M. C. Zounes and David J. Ecker, "Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection", *Nucleic Acids Res.* **19**, 5743-5748 (1991).

C. J. Guinosso, G. D. Hoke, S. Freier, J. F. Martin, D. J. Ecker, C. K. Mirabelli, S. T. Crooke and P. D. Cook, "Synthesis and Biophysical and Biological Evaluation of 2'-Modified Antisense Oligonucleotides", *Nucleosides & Nucleotides* **10**, 259-262 (1991).

Ming-Yi Chiang, Hedy Chan, Mary Ann Zounes, Susan M. Freier, Walt F. Lima and C. Frank Bennett, "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms" *J. Biol. Chem.* **266**, 18162,18171 (1991).

Susan M. Freier, Walt F. Lima, Yogesh S. Sanghvi, Timothy Vickers, Maryann Zounes, P. Dan Cook and David J. Ecker, "Thermodynamics of Antisense Oligonucleotide Hybridization", in *Gene Regulation: Biology of Antisense RNA and DNA*, R. P. Erickson and J. G. Izant, eds, Raven Press, New York, 95-107 (1992).

Brett P. Monia, Joseph F. Johnston, David J. Ecker, Mary Ann Zounes, Walt F. Lima and Susan M. Freier, "Selective Inhibition of Mutant Ha-ras mRNA Expression by Antisense Oligonucleotides", *J. Biol. Chem.* **267**, 19954-19962 (1992).

D. J. Ecker, T. A. Vickers, T. W. Bruice, S. M. Freier, R. D. Jenison, M. Manoharan and M. Zounes, "Pseudo-Half-Knot Formation with RNA", *Science* **257**, 958-961 (1992).

Walt F. Lima, Brett, P. Monia, David J. Ecker and Susan M. Freier, "Implication of RNA Structure on Antisense Oligonucleotide Hybridization Kinetics", *Biochemistry* **31**, 12055-12061 (1992).

Andrew M. Kawasaki, Martin D. Casper, Susan M. Freier, Elena A. Lesnik, Maryann C. Zounes, Lendell L. Cummins, Carolyn Gonzalez and P. Dan Cook, "Uniformly Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets", *J. Med. Chem.* **36**, 831-841 (1993).

Susan M. Freier, "Hybridization: Considerations Affecting Antisense Drugs", in *Antisense Research and Applications*, S.T. Crooke & B. Lebleu, eds. CRC Press, Boca Raton, FA., 67-82 (1993).

Elena A. Lesnik, Charles J. Guinasso, Andrew M. Kawasaki, Henri Sasmor, Maryann Zounes, Lendell L. Cummins, David J. Ecker, P. Dan Cook and Susan M. Freier, "Oligodeoxynucleotides Containing 2'-O-Modified Adenosine: Synthesis and Effects on Stability of DNA:RNA Duplexes", *Biochemistry*, **32**, 7832-7838 (1993).

Alain De Mesmaeker, Jacques Lebreton, Pascale Hoffman and Susan M. Freier, "Stereocontrolled Synthesis of 2'- α -C-Branched Nucleoside Analogues and their Incorporation into Oligodeoxyribonucleotides", *Synlett*, 677-679, (1993).

Brett P. Monia, Elena A. Lesnik, Carolyn Gonzalez, Walt F. Lima, Danny McGee, Charles J. Guinasso, Andrew M. Kawasaki, P. Dan Cook and Susan M. Freier, "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression", *J. Biol. Chem.* **268**, 14514-14522 (1993).

Yogesh, S. Sanghvi, Glenn D. Hoke, Susan M. Freier, Maryann C. Zounes, Carolyn Gonzalez, Lendell Cummins, Henri Sasmor and P. D. Cook, "Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines", *Nucleic Acids Res.* **21**, 3197-3203 (1993)

M. J. Graham, S. M. Freier, R. M. Crooke, D. J. Ecker, R. N. Maslova and E. A. Lesnik, "Tritium Labeling of Antisense Oligonucleotides by Exchange with Tritiated Water", *Nucleic Acids Res.*, **21**, 3737-3743 (1993).

Michael Egholm, Ole Buchardt, Leif Christensen, Carsten Behrens, Susan M. Freier, David A. Driver, Rolf H. Berg, Seong K. Kim, Bengt Norden and Peter E. Nielsen, "PNA Hybridizes to Complimentary Oligonucleotides Obeying the Watson-Crick Hydrogen Bonding Rules", *Nature*, **365**, 566-568 (1993).

Jacques Lebreton, Alain De Mesmaeker, Adrian Waldner, Valérie Fritsch, Romain M. Wolf and Susan M. Freier, "Synthesis of Thymidine Dimer Derivatives Containing an Amide Linkage and their Incorporation into Oligodeoxyribonucleotides", *Tetrahedron Lett.* **34**, 6383-6386 (1993).

Alain De Mesmaeker, Jacques Lebreton, Adrian Waldner, Valérie Fritsch, Romain M. Wolf and Susan M. Freier, "Amides as Substitute for the Phosphodiester Linkage in Antisense Oligonucleotides", *Synlett*, 733-735, (1993).

Kanda S. Ramasamy, Maryann Zounes, Carolyn Gonzalez, Susan M. Freier, Elena, A. Lesnik, Lendell L. Cummins, Richard H. Griffey, Brett P. Monia and P. Dan Cook, "Remarkable Enhancement of Binding Affinity of Heterocycle-Modified DNA to DNA and RNA. Synthesis Characterization and Biophysical Evaluation of N²-Imidazolylpropylguanine and N²-Imidazolylpropyl-2-aminoadenine Modified Oligonucleotides", *Tetrahedron Lett.*, **35** 215-218 (1994).

Muthiah Manoharan, Laura K. Johnson, C. Frank Bennett, Tim A. Vickers, David J. Ecker, Lex M. Cowser, Susan M. Freier and P. Dan Cook, "Cholic Acid-Oligonucleotide Conjugates for Antisense Applications", *Bioorganic & Medicinal Chemistry Letters*, **4**, 1053-1060 (1994).

Marc-Olivier Bévierre, Alain De Mesmaeker, Romain M. Wolf and Susan M. Freier, "Synthesis of 2'-O-Methyl-6,3'-Ethanouridine and its Introduction into Antisense Oligonucleotides", *Bioorg. Med. Chem. Lett.*, **4**,237-240 (1994).

Karl-Heinz Altmann, Susan M. Freier, Uwe Pies and Tammo Winkler, "The synthesis of N-acetyl pyrrolidino-thymidine and its incorporation into oligonucleotides", *Angew. Chem. Int. Ed. Engl.*, **33**, 1654-1657 (1994).

Alain De Mesmaeker, Adrian Waldner, Jacque Lebreton, Pascale Hoffmann, Valérie Fritsch, Romain M. Wolf and Susan M. Freier, "Amides as a New Type of Backbone Replacement in Oligonucleotides", *Angew. Chem. Int. Ed. Engl.*, **33**, 226-229 (1994).

R. Griffey, E. Lesnik, S. Freier, Y.S. Sanghvi, K. Teng, A. Kawasaki, C. Guinosso, P. Wheler, V. Mohan, "New twists on nucleic acids: structural properties of modified nucleosides incorporated into oligonucleotides" in ACS Symposium Series No. 580, pp 1-22, ACS Publication, Washington DC (1994).

Susan M. Freier, Danielle A. M. Konings, Jacqueline R. Wyatt and David J. Ecker, "Deconvolution of Combinatorial Libraries for Drug Discovery: A Model System." *J. Med. Chem.*, **38**, 344-352 (1995).

Michael C. Griffith, Lisa M. Risen, Michael Greig, Elena A. Lesnik, Kelly Sprankle, Rich Griffey, John S. Kiely and Susan M. Freier, "Mono and Bis PNA's as Triplexing Agents: Binding and Stoichiometry." *J. Amer. Chem Soc.*, **117**, 831-832 (1995).

Lendell L. Cummins, Steven R. Owens, Lixa M. Risen, Danny McGee, Charles Guinosso, Maryanne M. Zounes, Mike Greig, Elena A Lesnik, Susan M. Freier, Henri Sasmor, Richard H. Griffey, P. Dan Cook, "Effects of Uniform 2' Modification on Oligodeoxynucleotide Hybridization and Nuclease Sensitivity", *Nucleic Acids Res.*, **23**, 2019-2024 (1995).

Timothy A. Vickers, Michael C. Griffith, Kanda Ramasamy, Lisa M. Risen and Susan M. Freier, "Inhibition of NF- κ B specific transcriptional activation by PNA strand invasion", *Nucleic Acids Res.*, **23**, 3003-3008 (1995).

Yogesh S. Sanghvi, Laurent Bellon, François Morvan, Tomonori Hoshiko, Eric Swayze, Lendell Cummins, Susan Freier, Nicholas Dean, Brett Monia, Richard H. Griffey and P. Dan Cook, "Synthesis, Biophysical, and Biological Evaluations of Novel Antisense Oligonucleosides Containing Dephosphono-internucleosidic Linkages", *Nucleosides & Nucleotides*, **14**, 1087-1090 (1995).

Elena A. Lesnik and Susan M. Freier, "Relative thermodynamic stability of DNA, RNA and DNA:RNA hybrid duplexes, relationship with base composition and structure", *Biochemistry*, **34**, 10807-10815 (1995).

Jacqueline R. Wyatt, Peter W. Davis and Susan M. Freier, "Kinetics of G-quartet-mediated tetramer formation", *Biochemistry*, **35**, 8002-8008 (1996)

Susan M. Freier, Danielle A. M. Konings, Jacqueline R. Wyatt and David J. Ecker, "Mutational SURF: A Strategy for Improving Lead Compounds Identified from Combinatorial Libraries", *Bioorganic and Medicinal Chemistry*, **4**, 717-725 (1996).

Danielle A. M. Konings, Jacqueline R. Wyatt, David J. Ecker and Susan M. Freier, "Deconvolution of Combinatorial Libraries for Drug Discovery: Theoretical Comparison of Pooling Strategies", *J. Med. Chem.*, **39**, 2710-2719 (1996).

Laura A. Lingardo, Peter W. Davis, Normand Hébert, Kelly Sprankle, Thomas Brennan, David J. Ecker, Susan M. Freier and Jacqueline R. Wyatt, "Deconvolution of Combinatorial Libraries for Drug Discovery: Experimental Comparison of Pooling Strategies", *J. Med. Chem.*, **39**, 2720-2726 (1996).

Karl-Heinz Altmann, Nicholas M. Dean, Dorian Fabbro, Susan M. Freier, Thomas Geiger, Robert Häner, Dieter Hüskens, Pierre Martin, Brett P. Monia, Marcel Müller, François Natt, Paul Nicklin, Judy Phillips, Uwe Pieses, Henri Sasmor and Heinz E. Moser, "Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals", *Chimia*, **50**, 168-176 (1996).

Brett Monia, Henri Sasmor, Joseph F. Johnston, Susan M. Freier, Elena A. Lesnik, Marcel Muller, Karl-Heinz Altmann, Heinz Moser and Dorian Fabbro, "Sequence-Specific Antitumor Activity of a Phosphorothioate Oligodeoxynucleotide Targeted to Human C-raf Kinase Supports and Antisense Mechanism of Action *in vivo*", *Proc. Natl. Acad. Sci. USA*, **93**, 15481-15484 (1996).

Richard H. Griffey, Brett P. Monia, Lendall L. Cummins, Susan M. Freier, Michael J. Greig, Charles J. Guinasso, Elena Lesnik, Sherilynn M. Manalili, Venkatraman Mohan, Steven Owens, Bruce R. Ross, Henri Sasmor, Ed Wancewicz, Kurt Weiler, Patrick D. Wheeler and P. Dan Cook, "2'-O-Aminopropyl Ribonucleotides: A Zwitterionic Modification that Enhances the Exonuclease Resistance and Biological Activity of Antisense Oligonucleotides", *J. Med. Chem.*, **39**, 5100-5109.

Elena Lesnik, Fred Hassman, Julie Barbeau, Kelly Teng, Kurt Weiler, Richard Griffey and Susan Freier, "Triplex Formation Between DNA and Mixed Purine-Pyrimidine PNA Analog with Lysines in Backbone", *Nucleosides and Nucleotides*, **16**, 1775-1779 (1997)

Muthiah Manoharan, Laura K. Andrade, Venatraman, Mohan, Susan M. Freier and P. Dan Cook, "Oligonucleotide Conjugates Derived from an Electrophilic Site: Conjugation to Baseless Carbohydrate Residue. Synthesis, Hybridization and Modeling Studies", *Nucleosides and Nucleotides*, **16**, 1741-1744 (1997)

Elena A. Lesnik, Lisa M. Risen, David A. Driver, Michael C. Griffith, Kelly Sprankle and Susan M. Freier, "Evaluation of Pyrimidine PNA Binding to ssDNA Targets from Nonequilibrium Melting Experiments", *Nucleic Acids Res.*, **25**, 568-574 (1997).

Danielle A. M. Konings, Jacqueline R. Wyatt, David J. Ecker and Susan M. Freier, "Strategies for Rapid Deconvolution of Combinatorial Libraries: Comparative Evaluation Using a Model System" *J. Med. Chem.*, **40**, 4386-4395 (1997).

Susan M. Freier and Karl-Heinz Altmann, "The Ups And Downs Of Nucleic Acid Duplex Stability: Structure-Stability Studies On Chemically Modified DNA:RNA Duplexes", *Nucleic Acids Research*, **25**, 4429-4443 (1997).

Elena A. Lesnik and Susan M. Freier, "What Affects the Effect of 2'-Alkoxy Modifications? 1. Stabilization Effect of 2'-Methoxy Substitutions in Uniformly Modified DNA Oligonucleotides", *Biochemistry*, **37**, 6991-6997 (1998).

David J. Ecker and Susan M. Freier, "PNA, antisense, and antimicrobials", *Nature Biotechnology* **16**, 332 (1998).

Olga Matveeva, Brice Felden, Alexander Tsodikov, Joseph Johnston, Brett P. Monia, John Atkins, Raymond Gesteland and Susan M. Freier, "Prediction of antisense oligonucleotides efficacy by *in vitro* methods". *Nature Biotechnology*, **16**, 1374-5 (1998).

David H. Mathews, Mark E. Burkard , Susan M. Freier, Jacqueline R. Wyatt and Douglas H. Turner, "Predicting oligonucleotide affinity to nucleic acid targets." *RNA* **5**, 1458-69 (1999).

Emmanuel Beaulieu, Susan Freier, Jacqueline R. Wyatt, Jean-Michel Claverie and Daniel Gautheret, "Patterns of Variant Polyadenylation Signal Usage in Human Genes", *Genome Res.* **10**, 1001-10 (2000).

Timothy A. Vickers, Jacqueline R. Wyatt, and Susan M. Freier, " Effects of RNA Secondary Structure on Antisense Activity", *Nucleic Acids Res.* **28**,1340-1347 (2000).

O. V. Matveeva , A. D. Tsodikov, M. Giddings, S.M. Freier, J.R. Wyatt, A.N. Spiridonov, S.A. Shabalina, R.F. Gesteland and J. F. Atkins, "Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity", *Nucleic Acids Res.* **28**, 2862-2865 (2000).

Timothy A. Vickers, Jacqueline R. Wyatt, T. Burckin, C. Frank Bennett and Susan M. Freier, "Fully modified 2' MOE oligonucleotides redirect polyadenylation", *Nucleic Acids Res.* **29**, 1293-1299 (2001).


Richard S. Geary, Tanya A. Watanabe, LoAnne Truong, Sue Freier, Elena A. Lesnik, Namir B. Sioufi, Henri Sasmor, Muthiah Manoharan and Arthur A. Levin, "Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats", *J. Pharmacol. Exp. Ther.* **296**, 890-897 (2001).

Muthiah Manoharan, Elena Lesnik, Gopal B. Inamati, Namir B. Sioufi, and Susan M. Freier, "Improving Antisense Oligonucleotide Binding To Human Serum Albumin:Dramatic Effect of Conjugation of Ibuprofen to Oligonucleotides" *Chembiochem.* **3**, 1257-60 (2002)

Olga V. Matveeva, David H. Mathews, Alexander D Tsodikov, S. A. Shabalina³, Raymond F. Gesteland, John. F. Atkins and Susan M. Freier, "Thermodynamic criteria for high hit rate antisense oligonucleotide design", *Nucleic Acids Research* **31**, 4989-94 (2003).

Susan M. Freier "Methods of selecting sites in RNA for antisense targeting" in Antisense drug technology: Principles, strategies, and applications (ed. Crooke, S. T.), pp. 107-118. Marcel Dekker, New York (2001)


Human tyrosine kinase, non-receptor, 1, ID: 12436, Cell Line: T-24, Oligo Conc: 150 nM, Primer Probe
Set:RTS1356



Isis #

EXHIBIT 2

Rat urate anion exchanger 1, ID: 31543, Cell Line: Rin-M, Oligo Conc: 200 nM, Primer Probe
Set:RTS1642



Isis #

EXHIBIT 3